[New synthetic antithrombotic agent. In secondary prevention conclusive, too].
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077425:Fondaparinux; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy; D012307:Risk Factors; D013924:Thrombophlebitis / Q000188:drug therapy; D013997:Time Factors
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux